A mother-of-two from Ashford says she will struggle to cope after her disability benefit was cut. Yolanda Barker, who has multiple sclerosis, is one of thousands of people, who've been moved from Disability Living Allowance to Personal Independence Payment. It means she's lost almost one and half thousand pounds towards her care, every year. Tom Savvides talks to Yolanda Barker and Genevieve Edwards from the MS Society.
More than 1000 people in the South East are living with a condition that has no cure - multiple sclerosis. The disease is related to the nervous system and affects people differently. Some struggle to walk whilst others have vision or speech problems.
The Kent MS Centre in Canterbury has been offering support and therapies to ease the symptoms of MS for the last thirty years. Now, the charity has raised 1.6 million pounds to build a new bigger and better therapy centre - which will open by the end of 2014.
In this clip, two of the current members and fundraisers talk about living with MS and what the new centre means for them. Mary is a young mum from Ashford. Amy from Dover was diagnosed at the age of 15 and is training to be a nurse.
Work is underway to build a new therapy centre for people living with multiple sclerosis. For 30 years, a centre in Canterbury has been supporting those affected by the condition. But it was struggling to cope with increased demand for its services. So a decision was taken to expand.
It's taken fundraisers 15 years to raise the 1.6 million pounds needed to fund the new centre. Manager Karen Middlemiss explains what it means for people in Kent.
Every week 50 people will be diagnosed with Multiple sclerosis - a disease that has no cure. It affects people in different ways - memory loss, vision problems and some struggle to walk. For the last 30 years, one charity in Kent has been supporting those who are coping with the condition.
And now they're starting to build a new therapy centre. Our reporter Nashreen Issa went to see the centre and spoke to fundraiser Mary Daly, centre manager Karen Middlemiss and some of the members of the group in Canterbury.
Video. It is an illness that affects around 100,000 people in the UK but there is still no known cure for those who suffer day in, day out. Now a study has shown that people living with Multiple Sclerosis in the south could benefit from a unique combination of therapies.
The MS Society has given £40,000 to help fund the research, and volunteers have reported marked improvement in their mobility. Sally Simmonds explains.
A new drug has been approved by the European Medicines Agency which could offer better treatment to patients with multiple sclerosis. Alemtuzumab will give people who have the disease the chance to live without the side effects for much longer.
Symptoms of the disease can include loss of physical skills, sensation, vision and bladder control.
Professor Herman Waldmann was involved in the early discovery work of the antibody drug called Campath-1H at Cambridge University. It was originally used to treat leukaemia. He continued to study the drug for two decades while at Oxford University.
A man from Kent will travel almost 3,000 miles on hismotorbike in support of his wife who suffers from multiple sclerosis.
Paul Thomas will start his 7 day journey on June 1 at Folkestone harbour to raise money for the MS Society.
He will travel around the coast of Britain without using motorways.
Paul's wife Shelly was diagnosed with MS in 2001 and her symptoms include spasms, losing the use of legs and temporary blindness.
Shelly says she’s incredibly proud of her husband: “He has such a big heart and doing this challenge to raise money and awareness and show support for me and others with this condition is beyond words."
Scientists in Portsmouth are to launch a major study of little-known proteins they believe are a contributing factor to diseases such as dementia and multiple sclerosis.
The team of biologists at the University of Portsmouth have been awarded £600,000 to research the impact on the ageing of the brain and cognitive decline.
The study will focus on a protein known as Kir4.1 which is a key element in controlling special cells in the brain and spinal cord which form myelin, a substance which insulates the brain's wiring.